A common prostate cancer treatment called androgen deprivation therapy (ADT) is associated with bone decay. The therapy suppresses or blocks the production of male sex hormones that contribute to the growth of prostate cancer. Currently, about 600,000 prostate cancer patients in the United States are being treated with ADT.
Researchers examined 26 prostate cancer patients being treated with ADT. The investigators found evidence that the men had “structural decay of cortical (hard outer shell) and trabecular (spongy inner mesh) bone.
Sex steroid deficiency induced by ADT for prostate cancer results in micro architectural decay. Bone fragility in these men may be more closely linked to testosterone than estradiol deficiency. The researchers used a relatively new technology — high resolution peripheral quantitative CT imaging — that enabled them to take “virtual bone biopsies.”
This technology may be a useful test in predicting fractures in patients, but further research is needed in identifying individuals at greatest fracture risk as well as optimal therapeutic strategies.
[...] used to treat cancer, bevacizumab is associated with an increased risk of blood clots that can lead to heart attack or [...]
Pingback by Newer Therapies for Eye Disorder not jointly to Heart troubles « Pharmacy blogs, Pharmaceutical Products, Health care news — October 12, 2010 @ 7:37 pm
[...] correlation between Chronic Obstructive Pulmonary Disease (COPD) and lung cancer, but this is the first time such a link has been shown for asthma and lung cancer. However, based [...]
Pingback by Asthma related to Lung Cancer threat « Pharmacy blogs, Pharmaceutical Products, Health care news — November 9, 2010 @ 3:34 pm